1. Home
  2. MMLP vs SPRO Comparison

MMLP vs SPRO Comparison

Compare MMLP & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MMLP
  • SPRO
  • Stock Information
  • Founded
  • MMLP 2002
  • SPRO 2013
  • Country
  • MMLP United States
  • SPRO United States
  • Employees
  • MMLP N/A
  • SPRO N/A
  • Industry
  • MMLP Oil Refining/Marketing
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • MMLP Energy
  • SPRO Health Care
  • Exchange
  • MMLP Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • MMLP 139.6M
  • SPRO 162.1M
  • IPO Year
  • MMLP 2002
  • SPRO 2017
  • Fundamental
  • Price
  • MMLP $2.98
  • SPRO $2.66
  • Analyst Decision
  • MMLP
  • SPRO Buy
  • Analyst Count
  • MMLP 0
  • SPRO 4
  • Target Price
  • MMLP N/A
  • SPRO $5.00
  • AVG Volume (30 Days)
  • MMLP 15.9K
  • SPRO 1.2M
  • Earning Date
  • MMLP 07-16-2025
  • SPRO 08-04-2025
  • Dividend Yield
  • MMLP 0.67%
  • SPRO N/A
  • EPS Growth
  • MMLP N/A
  • SPRO N/A
  • EPS
  • MMLP N/A
  • SPRO N/A
  • Revenue
  • MMLP $719,335,000.00
  • SPRO $44,584,000.00
  • Revenue This Year
  • MMLP $4.19
  • SPRO N/A
  • Revenue Next Year
  • MMLP N/A
  • SPRO N/A
  • P/E Ratio
  • MMLP N/A
  • SPRO N/A
  • Revenue Growth
  • MMLP N/A
  • SPRO N/A
  • 52 Week Low
  • MMLP $2.56
  • SPRO $0.51
  • 52 Week High
  • MMLP $4.13
  • SPRO $3.22
  • Technical
  • Relative Strength Index (RSI)
  • MMLP 46.75
  • SPRO 60.75
  • Support Level
  • MMLP $2.99
  • SPRO $2.89
  • Resistance Level
  • MMLP $3.10
  • SPRO $3.22
  • Average True Range (ATR)
  • MMLP 0.08
  • SPRO 0.13
  • MACD
  • MMLP -0.01
  • SPRO -0.07
  • Stochastic Oscillator
  • MMLP 28.57
  • SPRO 12.64

About MMLP Martin Midstream Partners L.P. Limited Partnership

Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: